Following the agreement, it has reached with Université Laval and the CERVO Brain Research Centre of the CIUSSS de la Capitale Nationale, the venture capital fund will finance the development of a project on the SRSF3 target in the laboratory of Dr Jasna Kriz.
AmorChem is based Montreal, and focused on creating promising life science companies from technologies originating primarily from Quebec-based universities and research centres.
Launched in 2011, the AmorChem I Fund model combines access to financial resources with a virtual incubator structure that enables the rapid development and commercialisation of its technologies.
The first fund (41.2MUSD) has built a portfolio of 24 technologies and successfully transacted two pharma exits as well as spun-out six companies. The attractiveness of this seed fund model and the role it plays in the investment ecosystem were highlighted in September 2017 with the launch of the AmorChem II Fund, which now totals USD 45.7m.
Bonesupport Holding extends patient enrolment schedule for ongoing FORTIFY study
NKMax America announces launch of Phase I clinical trial of SNK in Mexico in patients with psoriasis
AstraZeneca reports positive results for Farxiga from phase III DAPA-HF trial
Cassiopea submits NDA to US FDA for clascoterone cream 1% acne treatment
Provention Bio names new senior vice president of Clinical Development
US FDA grants Moderna's mRNA-1893 fast track designation
Knopp Biosciences commences phase two trial of oral dexpramipexole
HedgePath Pharmaceuticals updates change in name and ticker symbol
Deciphera Pharmaceuticals concludes public offering at USD37.00 per share